327 related articles for article (PubMed ID: 27023922)
1. Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment.
Ishihara H; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
Target Oncol; 2016 Oct; 11(5):605-617. PubMed ID: 27023922
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
Clin Genitourin Cancer; 2017 Jun; 15(3):e437-e446. PubMed ID: 28188047
[TBL] [Abstract][Full Text] [Related]
3. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
4. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Kim SH; Kim S; Joo J; Seo HK; Joung JY; Lee KH; Chung J
BMC Cancer; 2016 Aug; 16():577. PubMed ID: 27484254
[TBL] [Abstract][Full Text] [Related]
8. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
[TBL] [Abstract][Full Text] [Related]
9. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K
Tumori; 2015; 101(5):555-9. PubMed ID: 26045121
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
Hudson JM; Bailey C; Atri M; Stanisz G; Milot L; Williams R; Kiss A; Burns PN; Bjarnason GA
Eur Radiol; 2018 Jun; 28(6):2281-2290. PubMed ID: 29383520
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.
Higgins MI; Martini DJ; Patil DH; Nabavizadeh R; Steele S; Williams M; Joshi SS; Narayan VM; Sekhar A; Psutka SP; Ogan K; Bilen MA; Master VA
Cancer; 2021 Jun; 127(12):1974-1983. PubMed ID: 33760232
[TBL] [Abstract][Full Text] [Related]
13. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma.
Raphael J; Thawer A; Bjarnason GA
Urol Oncol; 2018 Jan; 36(1):12.e1-12.e6. PubMed ID: 28966072
[TBL] [Abstract][Full Text] [Related]
15. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
Ivanyi P; Koenig J; Trummer A; Busch JF; Seidel C; Reuter CW; Ganser A; Grünwald V
World J Urol; 2016 Jul; 34(7):909-15. PubMed ID: 26586475
[TBL] [Abstract][Full Text] [Related]
16. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study.
Suo A; Iqbal U; Lim J; Lee C; Gesy K; Iqbal N; Abbas T
Clin Genitourin Cancer; 2017 Jun; 15(3):e397-e404. PubMed ID: 28216279
[TBL] [Abstract][Full Text] [Related]
18. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
20. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Lolli C; Basso U; Derosa L; Scarpi E; Sava T; Santoni M; Crabb SJ; Massari F; Aieta M; Conteduca V; Maruzzo M; La Russa F; Wheater M; Berardi R; Galli L; De Giorgi U
Oncotarget; 2016 Aug; 7(34):54564-54571. PubMed ID: 27409344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]